Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 30, Issue 3, 2005, Pages 171-174

  Tsivou, E ^a   Melakopoulos, I ^a   Kotsiou, A ^a   Anagnostopoulou, S ^a   Tesseromatis, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cephalosporins; Hyperlipidaemia; Ibuprofen; Mandible; Serum

Indexed keywords

ANTIBIOTIC AGENT; CEFALORIDINE; CEFALOTIN; CEFAPIRIN; CEFAZOLIN; CEPHALOSPORIN; FATTY ACID; IBUPROFEN; LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PLASMA PROTEIN; SERUM ALBUMIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; MANDIBLE; NONHUMAN; RAT;

EID: 27144513293     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190616     Document Type: Article

References (30)

1. Rahman MH, Yamasaki K, Shin YH, Lin CC, Otagiri M. Characterization of high affinity binding sites of non-steroidal antiinflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull 1993; 16(11):1169-74.
2. Rahim S, Aubry AF. Location of binding sites on immobilized human serum albumin for some nonsteroidal anti-inflammatory drugs. J Pharm Sci 1995; 84(8):949-52.
3. Padoin C, Tod M, Perret G, Petitjean O. Analysis of the pharmacokinetic interaction between cephalexin and quinapril by a nonlinear mixed-effect model. Antimicrob Agents Chemother 1998; 42(6):1463-9.
4. Nerli B, Pico G. Evidence of human serum albumin beta-lactamase activity. Biochem Mol Biol Int 1994; 32(4):789-95.
5. Tawara S, Matsumoto S, Matsumoto Y, Kamimura T, Goto S. Structure-binding relationship and binding sites of cephalosporins in human serum albumin. J Antibiot (Tokyo) 1992; 45(8):1346-57.
6. Nerli B, Romanini D, Pico G. Structural specificity requirements in the binding of beta-lactam antibiotics to human serum albumin. Chem Biol Interact 1997; 104(2-3):179-202.
7. Tesserommatis C, Tsopanakis C, Symeonoglou G, Loukissa M, Kouvarou E, Varonos DD. How harmless is FFA enhancement? Eur J Drug Metab Pharmacokinet 1996; 21(3):213-5.
8. Lee ZS, Critchley JA, Tomlinson B, Young RP, Thomas GN, Cockram CS, et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism; 50(2):135-43.
9. Janssen WM, Hillege H, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, de Jong PE. Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general population. Clin Chem Lab Med 2000; 38(11):1107-10.
10. Troconiz JI, Lopez-Bustamante LG, Fos D. Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat. Eur J Drug Metab Pharmacokinet 1993; 18(2):165-71.
11. Nakura H, Tateishi T, Watanabe M, Asoh M, Tanaka M, Kumai T, et al. Effect of hypoalbuminemia on the disposition of theophylline. Comparative study with Sprague-Dawley rats and a mutant Sprague-Dawley hyperlipidemic strain with hypoalbuminemia. Drug Metab Dispos 1998; 26(6):595-7.
12. Wojcicki J, Gornik W, Pawlik A, Drozdzik M, Gawronska-Szklarz B. Comparative pharmacokinetics of theophylline in rabbits and in humans with hyperlipidemia. Pulmon Pharmacol 1996; 9(3):175-8.
13. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int 2000; 57(suppl 75):S27-31.
14. Wojcicki J, Kalinowski W, Gawronska-Szklarz B. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneimittelforschung 1985; 35(6):991-3.
15. Thomas WA, Hartford WS, O'Neal RM. Modifications of diets responsible for induction of coronary thromboses and myocardial infarcts in rats. J Nutr 1959; 69:325-31.
16. Bennet VJ, Brondie LJ, Benner JE, Kirby MW. Simplified accurate method to antibiotic assay of clinical speciment. Appl Microbiol 1966; 14:170-7.
17. Trachilis A, Saranteas T, Potamianou A, Mourouzis C, Tesseromatis C. Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administrattion following surgical trauma. J Musculoskelet Neuronal Interact 2003; 3(2):170-5.
18. He YL, Tanigawara Y, Kamiya A, Hori R. Moment analysis of drug disposition in kidney. VI. Assessment of in vivo transmembrane transport of p-aminohippurate in tubular epithelium. J Pharmacokinet Biopharm 1991; 19(6):667-90.
19. Arvidsson A, Borga O, Alvan G. Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption. Clin Pharmacol Ther 1979; 25(6):870-6.
20. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB. A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S- transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol 2000; 56(5):383-8.
21. Hori R, Okumura K, Kamiya A, Nihira H, Nakano H. Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther 1983; 34(6):792-8.
22. Fong HJ, Cohen AH. Ibuprofen-induced acute renal failure with acute tubular necrosis. Am J Nephrol 1982; 2(1):28-31.
23. Trichilis A, Tesserommatis C, Varonos D. Changes in serum levels of quinolones in rats under the influence of experimental trauma. Eur J Drug Metab Pharmacokinet 2000; 25(2):73-8.
24. Jungbluth GL, Pasko MT, Jusko WJ. Factors affecting ceftriaxone plasma protein binding during open heart surgery. J Pharm Sci 1989; 78(10):807-11.
25. Terasaki T, Imaeda N, Nishide K, Tsuji A. Age-related change of cefazolin binding to rat serum proteins and its relation to the molar ratio of free fatty acid to serum albumin. J Pharmacobiodyn 1986; 9(1):81-7.
26. Kuroyama M, Motohashi S, Murase S, Kobayashi T, Tomonaga F, Abe T, et al. (In Japanese: Protein binding of cephems in the elderly). Nippon Ronen Igakkai Zasshi 1992; 29(11):874-80.
27. Kuroyama M, Kumano K, Tomonaga F, Sakai T, Mashimo S. (In Japanese: Protein binding of various cephems in healthy subjects and patients with chronic renal failure). Nippon Jinzo Gakkai Shi 1991; 33(8):769-77.
28. Decroix MO, Zini R, Chaumeil JC, Tillement JP. Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem Pharmacol 1988; 37(14):2807-14.
29. McNamara PJ, Trueb V, Stoeckel K. Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam Biochem Pharmacol 1990; 40(6):1247.
30. Tesseromati C, Triandafilidi E, Tsivou E. (In Greek: Serum and mandible alterations of antibiotics levels under increased serum FFA). Hell Stomatol Chron 1988; 32(2):103-9.